Onatasertib
As of the edition of 20 October 2026, Onatasertib is a small molecule: stopped in 2023; acts on MTOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 9, 3 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Immune system; Lungs and airways; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Onatasertib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MTOR | Serine/threonine-protein kinase mTOR | P42345 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 5 | 1 | 0 | 2 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2010 to now |
| Antengene | Lead sponsor of trials | 2018 to now |
| Shanghai Antengene | Lead sponsor of trials | 2021 to now |